<DOC>
	<DOCNO>NCT00520325</DOCNO>
	<brief_summary>The goal clinical research study find dose EZN-2232 give MBL deficient pediatric cancer patient undergo chemotherapy . The pharmacokinetics , pharmacodynamics , safety study drug also study .</brief_summary>
	<brief_title>A Study Safety , Tolerability , Pk rhMBL Pediatric Hematology/Oncology Pts With Fever Neutropenia</brief_title>
	<detailed_description>MBL deficient patient randomize ratio 1:1 receive single dose either 0.5 mg/kg 1.0 mg/kg intravenous rhMBL . A total 24 patient treated rhMBL arm , ( 12 0.5 mg/kg 12 1.0 mg/kg . All patient receive anti-infectious prophylactic supportive therapy per institutional standard</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<criteria>Patients must meet follow criterion eligible enrollment study : Children age 2 17 receive chemotherapy hematological/oncological disease . Patients must document MBL level &lt; 300 ng/mL serum evaluate screen protocol . Fever define oral temperature equivalent &gt; 100.4°F ( 38°C ) . Neutropenia define absolute neutrophil count ≤1,000/mm3 anticipation count fall 500/mm3 . Receiving broad spectrum antibiotic fever neutropenia . Patients ageadjusted normal serum creatinine OR creatinine clearance &gt; 60 mL/min/1.73m2 . Informed consent patient , parent legally authorize representative obtain prior entry . Reliable willing make available duration study abide study restriction . Patients meet follow exclusion criterion eligible enrollment . Patients receive preparative regimen bone marrow hematopoietic stem cell transplantation . Concurrent serious illness opinion principal investigator could potentially interfere protocol compliance . Patient pregnant , breast feeding planning pregnancy course study . Sexually active male female patient use acceptable barrier method contraception practice abstinence throughout study least 30 day receive last treatment unless patient surgically medically sterile . Patients moderate severe liver disease , define : AST ALT &gt; 5 time upper limit normal ( ULN ) OR Total bilirubin &gt; 2.5 time ULN . Patients poor venous access would preclude intravenous drug delivery multiple blood draw . Current participation another clinical study investigational agent and/or use investigational drug ( include investigational use FDA approve drug ) 30 day schedule administration rhMBL . Known allergic reaction MBL human plasma product . Patients hemodialysis unable tolerate volume IV fluid nondialysis day .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>MBL deficient oncologic hematologic pediatric fever neutropenia</keyword>
</DOC>